Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Younger age as a prognostic indicator in breast cancer: A cohort study

Authors: Elrasheid AH Kheirelseid, Jennifer ME Boggs, Catherine Curran, Ronan W Glynn, Cara Dooley, Karl J Sweeney, Michael J Kerin

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

The debate continues as to whether younger women who present with breast cancer have a more aggressive form of disease and a worse prognosis. The objectives of this study were to determine the incidence of breast cancer in women under 40 years old and to analyse the clinicopathological characteristics and outcome compared to an older patient cohort.

Methods

Data was acquired from a review of charts and the prospectively reviewed GUH Department of Surgery database. Included in the study were 276 women diagnosed with breast cancer under the age of forty and 2869 women over forty. For survival analysis each women less than 40 was matched with two women over forty for both disease stage and grade.

Results

The proportion of women diagnosed with breast cancer under the age of forty in our cohort was 8.8%. In comparison to their older counterparts, those under forty had a higher tumour grade (p = 0.044) and stage (p = 0.046), a lower incidence of lobular tumours (p < 0.001), higher estrogen receptor negativity (p < 0.001) and higher HER2 over-expression (p = 0.002); there was no statistical difference as regards tumour size (p = 0.477). There was no significant difference in overall survival (OS) for both groups; and factors like tumour size (p = 0.026), invasion (p = 0.026) and histological type (p = 0.027), PR (p = 0.031) and HER2 (p = 0.002) status and treatment received were independent predictors of OS

Conclusion

Breast cancer in younger women has distinct histopathological characteristics; however, this does not result in a reduced survival in this population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. Ca-a Cancer Journal for Clinicians. 2005, 55 (2): 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. Ca-a Cancer Journal for Clinicians. 2005, 55 (2): 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed
2.
go back to reference Swanson GM, Lin CS: Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr. 1994, 16: 69-77.PubMed Swanson GM, Lin CS: Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr. 1994, 16: 69-77.PubMed
3.
go back to reference Brinton LA, Sherman ME, Carreon JD, Anderson WF: Recent Trends in Breast Cancer Among Younger Women in the United States. Journal of the National Cancer Institute. 2008, 100 (22): 1643-1648. 10.1093/jnci/djn344.CrossRefPubMedPubMedCentral Brinton LA, Sherman ME, Carreon JD, Anderson WF: Recent Trends in Breast Cancer Among Younger Women in the United States. Journal of the National Cancer Institute. 2008, 100 (22): 1643-1648. 10.1093/jnci/djn344.CrossRefPubMedPubMedCentral
4.
go back to reference Chung M, Chang HR, Bland KI, Wanebo HJ: Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996, 77 (1): 97-103. 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3.CrossRefPubMed Chung M, Chang HR, Bland KI, Wanebo HJ: Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996, 77 (1): 97-103. 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3.CrossRefPubMed
5.
go back to reference Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E: Breast cancer in young women: clinicopathological features and biological specificity. Breast. 2003, 12 (4): 247-250. 10.1016/S0960-9776(03)00095-X.CrossRefPubMed Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E: Breast cancer in young women: clinicopathological features and biological specificity. Breast. 2003, 12 (4): 247-250. 10.1016/S0960-9776(03)00095-X.CrossRefPubMed
6.
go back to reference Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA: Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease. Journal of the American College of Surgeons. 2009, 208 (3): 341-347. 10.1016/j.jamcollsurg.2008.12.001.CrossRefPubMedPubMedCentral Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA: Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease. Journal of the American College of Surgeons. 2009, 208 (3): 341-347. 10.1016/j.jamcollsurg.2008.12.001.CrossRefPubMedPubMedCentral
7.
go back to reference Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H: Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment. PLoS One. 2009, 4 (11): A38-A46.CrossRef Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H: Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment. PLoS One. 2009, 4 (11): A38-A46.CrossRef
8.
go back to reference Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST: Stage 0 to stage III breast cancer in young women. Journal of the American College of Surgeons. 2000, 190 (5): 523-529. 10.1016/S1072-7515(00)00257-X.CrossRefPubMed Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST: Stage 0 to stage III breast cancer in young women. Journal of the American College of Surgeons. 2000, 190 (5): 523-529. 10.1016/S1072-7515(00)00257-X.CrossRefPubMed
9.
go back to reference Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY: Do young breast cancer patients have worse outcomes?. Journal of Surgical Research. 2003, 113 (1): 109-113. 10.1016/S0022-4804(03)00179-3.CrossRefPubMed Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY: Do young breast cancer patients have worse outcomes?. Journal of Surgical Research. 2003, 113 (1): 109-113. 10.1016/S0022-4804(03)00179-3.CrossRefPubMed
10.
go back to reference Kimura M, Yanagita Y, Fujisawa T, Koida T: Study of time-course changes in annual recurrence rates for breast cancer: Data analysis of 2,209 patients for 10 years post-surgery. Breast Cancer Research and Treatment. 2007, 106 (3): 407-411. 10.1007/s10549-007-9510-2.CrossRefPubMed Kimura M, Yanagita Y, Fujisawa T, Koida T: Study of time-course changes in annual recurrence rates for breast cancer: Data analysis of 2,209 patients for 10 years post-surgery. Breast Cancer Research and Treatment. 2007, 106 (3): 407-411. 10.1007/s10549-007-9510-2.CrossRefPubMed
11.
go back to reference Daniel SR, Armstrong K, Silber JH, Rosenbaum PR: An Algorithm for Optimal Tapered Matching, With Application to Disparities in Survival. Journal of Computational and Graphical Statistics. 2008, 17 (4): 914-924. 10.1198/106186008X385806.CrossRefPubMedPubMedCentral Daniel SR, Armstrong K, Silber JH, Rosenbaum PR: An Algorithm for Optimal Tapered Matching, With Application to Disparities in Survival. Journal of Computational and Graphical Statistics. 2008, 17 (4): 914-924. 10.1198/106186008X385806.CrossRefPubMedPubMedCentral
12.
go back to reference R Development Core Team: R: A Language and Environment for Statistical Computing. 2008, Vienna, Austria: R Foundation for Statistical computing R Development Core Team: R: A Language and Environment for Statistical Computing. 2008, Vienna, Austria: R Foundation for Statistical computing
13.
go back to reference Bharat A, Aft RL, Gao F, Margenthaler JA: Patient and Tumor Characteristics Associated With Increased Mortality in Young Women (< = 40 Years) With Breast Cancer. Journal of Surgical Oncology. 2009, 100 (3): 248-251. 10.1002/jso.21268.CrossRefPubMed Bharat A, Aft RL, Gao F, Margenthaler JA: Patient and Tumor Characteristics Associated With Increased Mortality in Young Women (< = 40 Years) With Breast Cancer. Journal of Surgical Oncology. 2009, 100 (3): 248-251. 10.1002/jso.21268.CrossRefPubMed
14.
go back to reference Foo CS, Su D, Chong CK, Chng HC, Tay KH, Low SC, Tan SM: Breast cancer in young Asian women: Study on survival. Anz Journal of Surgery. 2005, 75 (7): 566-572. 10.1111/j.1445-2197.2005.03431.x.CrossRefPubMed Foo CS, Su D, Chong CK, Chng HC, Tay KH, Low SC, Tan SM: Breast cancer in young Asian women: Study on survival. Anz Journal of Surgery. 2005, 75 (7): 566-572. 10.1111/j.1445-2197.2005.03431.x.CrossRefPubMed
15.
go back to reference Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, Piana L: Age as a Prognostic Factor in Breast-Cancer - Relationship to Pathological and Biologic Features. International Journal of Cancer. 1995, 62 (2): 138-144. 10.1002/ijc.2910620205.CrossRefPubMed Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, Piana L: Age as a Prognostic Factor in Breast-Cancer - Relationship to Pathological and Biologic Features. International Journal of Cancer. 1995, 62 (2): 138-144. 10.1002/ijc.2910620205.CrossRefPubMed
16.
go back to reference Xiong QH, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL: Female patients with breast carcinoma age 30 years and younger have a poor prognosis - The M. D. Anderson Cancer Center Experience. Cancer. 2001, 92 (10): 2523-2528. 10.1002/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6.CrossRefPubMed Xiong QH, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL: Female patients with breast carcinoma age 30 years and younger have a poor prognosis - The M. D. Anderson Cancer Center Experience. Cancer. 2001, 92 (10): 2523-2528. 10.1002/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6.CrossRefPubMed
17.
go back to reference Kollias J, Elston CW, Ellis IO, Robertson JFR, Blamey RW: Early-onset breast cancer - Histopathological and prognostic considerations. British Journal of Cancer. 1997, 75 (9): 1318-1323. 10.1038/bjc.1997.223.CrossRefPubMedPubMedCentral Kollias J, Elston CW, Ellis IO, Robertson JFR, Blamey RW: Early-onset breast cancer - Histopathological and prognostic considerations. British Journal of Cancer. 1997, 75 (9): 1318-1323. 10.1038/bjc.1997.223.CrossRefPubMedPubMedCentral
18.
go back to reference Yildirim E, Dalgic T, Berberoglu U: Prognostic significance of young age in breast cancer. Journal of Surgical Oncology. 2000, 74 (4): 267-272. 10.1002/1096-9098(200008)74:4<267::AID-JSO5>3.0.CO;2-N.CrossRefPubMed Yildirim E, Dalgic T, Berberoglu U: Prognostic significance of young age in breast cancer. Journal of Surgical Oncology. 2000, 74 (4): 267-272. 10.1002/1096-9098(200008)74:4<267::AID-JSO5>3.0.CO;2-N.CrossRefPubMed
19.
go back to reference McAree B, O'Donnell ME, Spence A, Lioe TF, McManus DT, Spence RA: Breast cancer in women under 40 years of age: a series of 57 cases from Northern Ireland. Breast. 2010, 19 (2): 97-104. 10.1016/j.breast.2009.12.002.CrossRefPubMed McAree B, O'Donnell ME, Spence A, Lioe TF, McManus DT, Spence RA: Breast cancer in women under 40 years of age: a series of 57 cases from Northern Ireland. Breast. 2010, 19 (2): 97-104. 10.1016/j.breast.2009.12.002.CrossRefPubMed
20.
go back to reference Leung GM, Thach TQ, Lam TH, Hedley AJ, Fielding R, Yip PSF, Lau EMC, Wong CM: Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. British Journal of Cancer. 2002, 87 (9): 982-988. 10.1038/sj.bjc.6600583.CrossRefPubMedPubMedCentral Leung GM, Thach TQ, Lam TH, Hedley AJ, Fielding R, Yip PSF, Lau EMC, Wong CM: Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. British Journal of Cancer. 2002, 87 (9): 982-988. 10.1038/sj.bjc.6600583.CrossRefPubMedPubMedCentral
21.
go back to reference Feldman AL, Welch JP: Long-term outcome in women less than 30 years of age with breast cancer. Journal of Surgical Oncology. 1998, 68 (3): 193-198. 10.1002/(SICI)1096-9098(199807)68:3<193::AID-JSO12>3.0.CO;2-2.CrossRefPubMed Feldman AL, Welch JP: Long-term outcome in women less than 30 years of age with breast cancer. Journal of Surgical Oncology. 1998, 68 (3): 193-198. 10.1002/(SICI)1096-9098(199807)68:3<193::AID-JSO12>3.0.CO;2-2.CrossRefPubMed
22.
go back to reference Livi L, Meattini I, Saieva C, Borghesi S, Scotti V, Petrucci A, Rampini A, Marrazzo L, Di Cataldo V, Bianchi S, et al: The impact of young age on breast cancer outcome. Eur J Surg Oncol. 2010 Livi L, Meattini I, Saieva C, Borghesi S, Scotti V, Petrucci A, Rampini A, Marrazzo L, Di Cataldo V, Bianchi S, et al: The impact of young age on breast cancer outcome. Eur J Surg Oncol. 2010
23.
go back to reference Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Oei SB, Peterse HL, Pierart M, Poortmans PM, et al: Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. European Journal of Cancer. 2003, 39 (7): 932-944. 10.1016/S0959-8049(03)00123-0.CrossRefPubMed Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Oei SB, Peterse HL, Pierart M, Poortmans PM, et al: Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. European Journal of Cancer. 2003, 39 (7): 932-944. 10.1016/S0959-8049(03)00123-0.CrossRefPubMed
24.
go back to reference Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, et al: Very young women (< 35 years) with operable breast cancer: features of disease at presentation. Annals of Oncology. 2002, 13 (2): 273-279. 10.1093/annonc/mdf039.CrossRefPubMed Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, et al: Very young women (< 35 years) with operable breast cancer: features of disease at presentation. Annals of Oncology. 2002, 13 (2): 273-279. 10.1093/annonc/mdf039.CrossRefPubMed
25.
go back to reference Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: a critical review. Journal of Clinical Oncology. 2008, 26 (15): 2568-2581. 10.1200/JCO.2007.13.1748.CrossRefPubMed Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: a critical review. Journal of Clinical Oncology. 2008, 26 (15): 2568-2581. 10.1200/JCO.2007.13.1748.CrossRefPubMed
26.
go back to reference Kwong A, Cheung P, Chan S, Lau S: Breast Cancer in Chinese Women Younger than Age 40: Are They Different from Their Older Counterparts?. World Journal of Surgery. 2008, 32 (12): 2554-2561. 10.1007/s00268-008-9589-6.CrossRefPubMed Kwong A, Cheung P, Chan S, Lau S: Breast Cancer in Chinese Women Younger than Age 40: Are They Different from Their Older Counterparts?. World Journal of Surgery. 2008, 32 (12): 2554-2561. 10.1007/s00268-008-9589-6.CrossRefPubMed
27.
go back to reference Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, et al: Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. Journal of Clinical Oncology. 2005, 23 (1): 41-48.CrossRefPubMed Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, et al: Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. Journal of Clinical Oncology. 2005, 23 (1): 41-48.CrossRefPubMed
28.
go back to reference van Nes JG, van de Velde CJ: The preferred treatment for young women with breast cancer--mastectomy versus breast conservation. Braest. 2006, 15 (Suppl 2): S3-10. van Nes JG, van de Velde CJ: The preferred treatment for young women with breast cancer--mastectomy versus breast conservation. Braest. 2006, 15 (Suppl 2): S3-10.
29.
go back to reference Zhou P, Gautam S, Recht A: Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Research and Treatment. 2007, 101 (1): 51-57. 10.1007/s10549-006-9268-y.CrossRefPubMed Zhou P, Gautam S, Recht A: Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Research and Treatment. 2007, 101 (1): 51-57. 10.1007/s10549-006-9268-y.CrossRefPubMed
30.
go back to reference EBCTCG: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet. 2000, 355 (9217): 1757-1770.CrossRef EBCTCG: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet. 2000, 355 (9217): 1757-1770.CrossRef
31.
go back to reference Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 366 (9503): 2087-2106.CrossRefPubMed Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 366 (9503): 2087-2106.CrossRefPubMed
32.
go back to reference Masinghe SP, Faluyi OO, Kerr GR, Kunkler IH: Breast radiotherapy for occult breast cancer with axillary nodal metastases--does it reduce the local recurrence rate and increase overall survival?. Clinical Oncology. 2011, 23 (2): 95-100. 10.1016/j.clon.2010.10.001.CrossRefPubMed Masinghe SP, Faluyi OO, Kerr GR, Kunkler IH: Breast radiotherapy for occult breast cancer with axillary nodal metastases--does it reduce the local recurrence rate and increase overall survival?. Clinical Oncology. 2011, 23 (2): 95-100. 10.1016/j.clon.2010.10.001.CrossRefPubMed
33.
go back to reference Yang PS, Chen CM, Liu MC, Jian JM, Horng CF, Liu MJ, Yu BL, Lee MY, Chi CW: Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys. 2009, 77 (2): 516-522.CrossRefPubMed Yang PS, Chen CM, Liu MC, Jian JM, Horng CF, Liu MJ, Yu BL, Lee MY, Chi CW: Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys. 2009, 77 (2): 516-522.CrossRefPubMed
34.
go back to reference Kunkler IH, Williams LJ, King CC, Jack W: Breast radiotherapy: considerations in older patients. Clinical Oncology. 2009, 21 (2): 111-117. 10.1016/j.clon.2008.11.012.CrossRefPubMed Kunkler IH, Williams LJ, King CC, Jack W: Breast radiotherapy: considerations in older patients. Clinical Oncology. 2009, 21 (2): 111-117. 10.1016/j.clon.2008.11.012.CrossRefPubMed
35.
go back to reference Kyndi M, Overgaard M, Nielsen HM, Sørensen FB, Knudsen H, Overgaard J: High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol. 2009, 90 (1): 74-79. 10.1016/j.radonc.2008.04.014.CrossRefPubMed Kyndi M, Overgaard M, Nielsen HM, Sørensen FB, Knudsen H, Overgaard J: High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol. 2009, 90 (1): 74-79. 10.1016/j.radonc.2008.04.014.CrossRefPubMed
36.
go back to reference Overgaard M: Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol. 1999, 9 (3): 292-299. 10.1016/S1053-4296(99)80022-8.CrossRefPubMed Overgaard M: Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol. 1999, 9 (3): 292-299. 10.1016/S1053-4296(99)80022-8.CrossRefPubMed
37.
go back to reference Overgaard M, Nielsen HM, Overgaard J: Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007, 82 (3): 247-253. 10.1016/j.radonc.2007.02.001.CrossRefPubMed Overgaard M, Nielsen HM, Overgaard J: Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007, 82 (3): 247-253. 10.1016/j.radonc.2007.02.001.CrossRefPubMed
38.
go back to reference Whelan T, Levine M: More evidence that locoregional radiation therapy improves survival: what should we do?. J Natl Cancer Inst Monogr. 2005, 97 (2): 82-84.CrossRef Whelan T, Levine M: More evidence that locoregional radiation therapy improves survival: what should we do?. J Natl Cancer Inst Monogr. 2005, 97 (2): 82-84.CrossRef
39.
go back to reference Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, et al: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst Monogr. 2005, 97 (2): 116-126.CrossRef Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, et al: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst Monogr. 2005, 97 (2): 116-126.CrossRef
40.
go back to reference Menard S, Casalini P, Cascinelli N, Balsari A: Breast carcinoma in young patients. Lancet. 2000, 356 (9235): 1113-1113.CrossRefPubMed Menard S, Casalini P, Cascinelli N, Balsari A: Breast carcinoma in young patients. Lancet. 2000, 356 (9235): 1113-1113.CrossRefPubMed
41.
go back to reference Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, et al: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998, 352 (9132): 930-942.CrossRef Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, et al: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998, 352 (9132): 930-942.CrossRef
42.
go back to reference EBCTCG: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365 (9472): 1687-1717.CrossRef EBCTCG: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365 (9472): 1687-1717.CrossRef
43.
go back to reference Andersson M, Kamby C, Jensen MB, Mouridsen H, Ejlertsen B, Dombernowsky P, Rose C, Cold S, Overgaard M, Andersen J, et al: Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-Operative Group DBCG 82B trial. European Journal of Cancer. 1999, 35 (12): 1659-1666. 10.1016/S0959-8049(99)00141-0.CrossRefPubMed Andersson M, Kamby C, Jensen MB, Mouridsen H, Ejlertsen B, Dombernowsky P, Rose C, Cold S, Overgaard M, Andersen J, et al: Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-Operative Group DBCG 82B trial. European Journal of Cancer. 1999, 35 (12): 1659-1666. 10.1016/S0959-8049(99)00141-0.CrossRefPubMed
44.
go back to reference Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD: Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. Journal of Clinical Oncology. 2006, 24 (9): 1332-1341.CrossRefPubMed Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD: Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. Journal of Clinical Oncology. 2006, 24 (9): 1332-1341.CrossRefPubMed
45.
go back to reference Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, et al: Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. European Journal of Cancer. 2007, 43 (2): 331-340. 10.1016/j.ejca.2006.10.009.CrossRefPubMed Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, et al: Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. European Journal of Cancer. 2007, 43 (2): 331-340. 10.1016/j.ejca.2006.10.009.CrossRefPubMed
46.
go back to reference Margolin KA, Liu PY, Unger JM, Fletcher WS, Flaherty LE, Urba WJ, Hersh EM, Hutchins LE, Sosman JA, Smith JW, et al: Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. Journal of Cancer Research and Clinical Oncology. 1999, 125 (5): 292-296. 10.1007/s004320050276.CrossRefPubMed Margolin KA, Liu PY, Unger JM, Fletcher WS, Flaherty LE, Urba WJ, Hersh EM, Hutchins LE, Sosman JA, Smith JW, et al: Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. Journal of Cancer Research and Clinical Oncology. 1999, 125 (5): 292-296. 10.1007/s004320050276.CrossRefPubMed
47.
go back to reference Anderson BO, Senie RT, Vetto JT, Wong GY, McCormick B, Borgen PI: Improved Survival in Young-Women with Breast-Cancer. Annals of Surgical Oncology. 1995, 2 (5): 407-415. 10.1007/BF02306373.CrossRefPubMed Anderson BO, Senie RT, Vetto JT, Wong GY, McCormick B, Borgen PI: Improved Survival in Young-Women with Breast-Cancer. Annals of Surgical Oncology. 1995, 2 (5): 407-415. 10.1007/BF02306373.CrossRefPubMed
49.
go back to reference Abe O, Abe R, Asaishi K, Enomoto K, Hattori T, Ino Y, Kikuchi K, Koyama H, Sawa K, Uchino J, et al: Systemic Treatment of Early Breast-Cancer by Hormonal, Cytotoxic, or Immune Therapy - 133 Randomized Trials Involving 31000 Recurrences and 24000 Deaths among 75000 Women .2. Lancet. 1992, 339 (8785): 71-85. Abe O, Abe R, Asaishi K, Enomoto K, Hattori T, Ino Y, Kikuchi K, Koyama H, Sawa K, Uchino J, et al: Systemic Treatment of Early Breast-Cancer by Hormonal, Cytotoxic, or Immune Therapy - 133 Randomized Trials Involving 31000 Recurrences and 24000 Deaths among 75000 Women .2. Lancet. 1992, 339 (8785): 71-85.
50.
go back to reference Chia S, Bryce C, Gelmon K: The 2000 EBCTCG overview: a widening gap. Lancet. 2005, 365 (9472): 1665-1666. 10.1016/S0140-6736(05)66524-5.CrossRefPubMed Chia S, Bryce C, Gelmon K: The 2000 EBCTCG overview: a widening gap. Lancet. 2005, 365 (9472): 1665-1666. 10.1016/S0140-6736(05)66524-5.CrossRefPubMed
Metadata
Title
Younger age as a prognostic indicator in breast cancer: A cohort study
Authors
Elrasheid AH Kheirelseid
Jennifer ME Boggs
Catherine Curran
Ronan W Glynn
Cara Dooley
Karl J Sweeney
Michael J Kerin
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-383

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine